CN106986869A - 用于抗病毒治疗的化合物和方法 - Google Patents

用于抗病毒治疗的化合物和方法 Download PDF

Info

Publication number
CN106986869A
CN106986869A CN201710094970.6A CN201710094970A CN106986869A CN 106986869 A CN106986869 A CN 106986869A CN 201710094970 A CN201710094970 A CN 201710094970A CN 106986869 A CN106986869 A CN 106986869A
Authority
CN
China
Prior art keywords
alkyl
compound
cycloalkyl
aryl
heterocyclic radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710094970.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·谢格尔
D·斯佩兰迪奥
杨海
M·桑吉
J·P·帕里什
许汉中
R·L·麦克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN106986869A publication Critical patent/CN106986869A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201710094970.6A 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法 Pending CN106986869A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625480P 2012-04-17 2012-04-17
US61/625,480 2012-04-17
CN201380030470.6A CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380030470.6A Division CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Publications (1)

Publication Number Publication Date
CN106986869A true CN106986869A (zh) 2017-07-28

Family

ID=48190648

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710094970.6A Pending CN106986869A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法
CN201380030470.6A Pending CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380030470.6A Pending CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Country Status (24)

Country Link
US (4) US8980878B2 (enExample)
EP (1) EP2838900B1 (enExample)
JP (3) JP2015516976A (enExample)
KR (2) KR102181318B1 (enExample)
CN (2) CN106986869A (enExample)
AU (1) AU2013249280B2 (enExample)
CA (1) CA2870024C (enExample)
CY (1) CY1122292T1 (enExample)
DK (1) DK2838900T3 (enExample)
EA (1) EA027855B1 (enExample)
ES (1) ES2750153T3 (enExample)
HK (1) HK1209745A1 (enExample)
HR (1) HRP20191754T1 (enExample)
HU (1) HUE045727T2 (enExample)
IL (1) IL235062A0 (enExample)
IN (1) IN2014DN09173A (enExample)
LT (1) LT2838900T (enExample)
MX (1) MX355781B (enExample)
NZ (1) NZ701647A (enExample)
PL (1) PL2838900T3 (enExample)
PT (1) PT2838900T (enExample)
SG (2) SG10201610166VA (enExample)
SI (1) SI2838900T1 (enExample)
WO (1) WO2013158776A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
EA027855B1 (ru) * 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Соединения и способы для противовирусной терапии
EA038819B1 (ru) 2013-08-21 2021-10-25 Алиос Биофарма, Инк. Противовирусные соединения
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
WO2016055656A1 (en) * 2014-10-10 2016-04-14 Ablynx N.V. Methods of treating rsv infections
EA032081B1 (ru) * 2014-12-08 2019-04-30 Янссен Сайенсиз Айрлэнд Юси ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
WO2016091791A1 (en) * 2014-12-08 2016-06-16 Janssen Sciences Ireland Uc Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (rsv)
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
JP2018076234A (ja) * 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
SG11201808907PA (en) 2016-04-15 2018-11-29 Blueprint Medicines Corp Inhibitors of activin receptor-like kinase
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
MX390145B (es) 2016-10-06 2025-03-20 Orbus Therapeutics Inc Formulaciones para la administracion de eflornitina
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
BR112020006334A2 (pt) 2017-09-29 2020-09-24 Enanta Pharmaceuticals, Inc. combinação de agentes farmacêuticos como inibidores de rsv
JP7254821B2 (ja) * 2017-10-16 2023-04-10 ブリストル－マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
US11236086B2 (en) 2017-10-18 2022-02-01 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
TW201932470A (zh) * 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
KR20210005569A (ko) 2018-04-23 2021-01-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Rsv에 대한 활성을 갖는 헤테로방향족 화합물
CA3124783A1 (en) 2018-12-27 2020-07-02 Taisho Pharmaceutical Co., Ltd. Pyrazolo[1,5-a]pyrimidine macrocyclic compound
JP7744350B2 (ja) 2020-01-13 2025-09-25 バージ アナリティクス，インコーポレイテッド 置換ピラゾロ－ピリミジンおよびその使用
WO2022092141A1 (ja) * 2020-10-28 2022-05-05 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体
CN113264929B (zh) * 2021-05-02 2023-10-10 润生药业有限公司 一种噻托溴铵的制备方法
JP7454729B2 (ja) * 2022-04-27 2024-03-22 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
CN101460507A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 噻唑基-二氢-吲唑
CN101460167A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 用作pi3-激酶抑制剂的噻唑基-二氢-环戊二烯并吡唑
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011163518A1 (en) * 2010-06-24 2011-12-29 Gilead Sciences, Inc. Pyrazolo [1, 5 -a] pyrimidines as antiviral agents
CN102395579A (zh) * 2009-02-17 2012-03-28 百时美施贵宝公司 丙型肝炎病毒抑制剂

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
US5543413A (en) 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
PL318199A1 (en) 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
TWI225488B (en) 1999-12-21 2004-12-21 Janssen Pharmaceutica Nv Derivatives of homopiperidinyl substituted benzimidazole analogues
WO2003078435A1 (en) 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Llc Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
US7304068B2 (en) 2002-05-10 2007-12-04 Smithkline Beecham Corporation Substituted pyrazolo [1,5-A] pyrimidinyls and pharmaceutical uses therefore
CA2487211C (en) 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
DE10247271A1 (de) 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
US8598193B2 (en) 2003-12-24 2013-12-03 Biota Scientific Management Pty Ltd. Polycyclic agents for the treatment of respiratory syncytial virus infections
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
WO2008070447A2 (en) 2006-11-21 2008-06-12 Smithkline Beecham Corporation Anti-viral compounds
US20090238772A1 (en) 2007-12-13 2009-09-24 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection
US20110052562A1 (en) 2007-12-19 2011-03-03 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
BRPI0908529A2 (pt) 2008-02-26 2015-09-29 Novartis Ag composto orgânicos
JP5637982B2 (ja) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
EP2182081B1 (de) 2008-10-29 2014-01-22 Neue Materialien Bayreuth GmbH Verfahren zur thermischen Behandlung eines beschichteten Stahlblechkörpers
JP5762971B2 (ja) 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
CA2746943A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2010101246A1 (ja) 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
PE20110679A1 (es) 2009-06-11 2011-10-20 Abbvie Bahamas Ltd Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP2462135A1 (en) * 2009-08-07 2012-06-13 Janssen R&D Ireland Bis-benzimidazole derivatives as hepatitis c virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EP2575866A4 (en) * 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
SG186830A1 (en) * 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
EA027855B1 (ru) 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Соединения и способы для противовирусной терапии

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
CN101460507A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 噻唑基-二氢-吲唑
CN101460167A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 用作pi3-激酶抑制剂的噻唑基-二氢-环戊二烯并吡唑
CN102395579A (zh) * 2009-02-17 2012-03-28 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011163518A1 (en) * 2010-06-24 2011-12-29 Gilead Sciences, Inc. Pyrazolo [1, 5 -a] pyrimidines as antiviral agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN: "《STN-REGISTRY -L5》", 《STN-REGISTRY》 *

Also Published As

Publication number Publication date
HK1209745A1 (en) 2016-04-08
KR20140145615A (ko) 2014-12-23
US10174038B2 (en) 2019-01-08
AU2013249280B2 (en) 2017-10-12
HK1207076A1 (en) 2016-01-22
ES2750153T3 (es) 2020-03-25
US20170029427A1 (en) 2017-02-02
MX355781B (es) 2018-04-30
US20130273037A1 (en) 2013-10-17
JP2017128596A (ja) 2017-07-27
US20150238501A1 (en) 2015-08-27
SG11201406736VA (en) 2015-03-30
IL235062A0 (en) 2014-12-31
JP2018095657A (ja) 2018-06-21
LT2838900T (lt) 2019-11-11
US8980878B2 (en) 2015-03-17
HRP20191754T1 (hr) 2020-01-24
EA201491889A1 (ru) 2015-03-31
DK2838900T3 (da) 2019-10-14
CA2870024A1 (en) 2013-10-24
WO2013158776A1 (en) 2013-10-24
EP2838900A1 (en) 2015-02-25
PT2838900T (pt) 2019-11-15
SG10201610166VA (en) 2017-01-27
IN2014DN09173A (enExample) 2015-07-10
JP6291103B2 (ja) 2018-03-14
JP2015516976A (ja) 2015-06-18
NZ701647A (en) 2016-05-27
SI2838900T1 (sl) 2019-10-30
KR102181318B1 (ko) 2020-11-20
AU2013249280A1 (en) 2014-11-06
US9504689B2 (en) 2016-11-29
CA2870024C (en) 2020-04-07
CN104583211A (zh) 2015-04-29
CY1122292T1 (el) 2021-01-27
KR20200044971A (ko) 2020-04-29
MX2014012450A (es) 2015-04-08
PL2838900T3 (pl) 2020-02-28
EP2838900B1 (en) 2019-08-21
US20170342079A1 (en) 2017-11-30
HUE045727T2 (hu) 2021-12-28
EA027855B1 (ru) 2017-09-29
KR102102283B1 (ko) 2020-04-21

Similar Documents

Publication Publication Date Title
CN106986869A (zh) 用于抗病毒治疗的化合物和方法
TWI626050B (zh) 吡唑並［１，５-ａ］嘧啶類之醫藥組成物與用途
JP2023535701A (ja) 抗ウイルス剤としての官能化ペプチド
CN102791693B (zh) 丙型肝炎病毒抑制剂
CN109641873B (zh) N-(吡啶-2-基)吡啶-磺酰胺衍生物及其用于疾病治疗的用途
CN105777754B (zh) 吡咯并嘧啶化合物
CN112105385A (zh) Irak降解剂和其用途
EP3209296B1 (en) Ethyl n-boc piperidinyl pyrazolo pyridones as janus kinase inhibitors
CN106795147B (zh) 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
TW202140494A (zh) 作為抗病毒劑之雜環化合物、藥物組合物及其用途
CN105189497B (zh) 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮
US20250188066A1 (en) Antiviral 1,3-di-oxo-indene compounds
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
WO2021218992A1 (zh) 取代的吡咯烷类化合物及其在药物中的应用
AU2023268460A1 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
HK40088987A (zh) 作为rho-激酶抑制剂的二氢呋喃并吡啶衍生物
HK1223914B (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170728

WD01 Invention patent application deemed withdrawn after publication